Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial

IMPORTANCE: The 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol identified patients with recent (past 12 months) myocardial infarction (MI) as very high risk, in whom a PCSK9 inhibitor is reasonable to add to maximally tole...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Gencer, Baris, Mach, François, Murphy, Sabina A., De Ferrari, Gaetano M., Huber, Kurt, Lewis, Basil S., Ferreira, Jorge, Kurtz, Christopher E., Wang, Huei, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S., Giugliano, Robert P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240652/
https://ncbi.nlm.nih.gov/pubmed/32432684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.0882
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados